Castle Biosciences is back in focus as some analysts move price targets from the mid $30s to around $52, while at least one fair value view at $48.5 remains unchanged. These shifts are being tied ...
Analysts have refreshed their view on JPMorgan Chase with an updated fair value estimate moving from US$328.09 to US$344.78, signaling a recalibration of what they see as a reasonable long term target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results